Proposed Keytruda biosimilar review, AI-designed metabolic medicines and WHO outbreak detection strategy.
Oncology and biosimilars
FDA accepts application for proposed Keytruda biosimilar
Zydus and Formycon announced that the FDA accepted their application for FYB206, a proposed pembrolizumab biosimilar, with a decision potentially expected in the third quarter of 2027. The companies followed an FDA-agreed development pathway without a comparative Phase III efficacy trial; FYB206 remains investigational and has not received regulatory approval.
Why it matters: Marks progress towards potential competition and wider access in oncology, while approval and commercial availability remain uncertain.
Zealand and Generate partner on AI-designed metabolic medicines
Zealand Pharma and Generate Biomedicines agreed to develop protein therapies targeting multiple biological pathways in obesity and other metabolic diseases. Generate will receive $30 million upfront, with further payments dependent on milestones, and lead research through candidate selection; Zealand will handle subsequent clinical development and commercialisation.
Why it matters: Shows how generative AI and laboratory validation are being combined in drug discovery, although clinical benefits have yet to be demonstrated.
WHO targets outbreak detection within 24 hours by 2030
WHO launched a five-year Pandemic Hub strategy aiming to help every country detect and understand emerging health threats within 24 hours by 2030. Its priorities include AI-supported monitoring, genomic surveillance and secure data sharing; achieving the target will require sustained investment and international cooperation.
Why it matters: Identifies practical priorities for public-health surveillance, diagnostic capacity and earlier responses to emerging infections.
Editorial summaries for general information only; not medical advice. Research findings and company announcements should be read in their original context.